Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Epidemiologic studies suggest that hepatocellular carcinoma (HCC) has a strong relationship with diabetes. However, the underlying molecular mechanisms still remain unclear. Here, we demonstrated that high glucose (HG), one of the main characteristics of diabetes, was capable of accelerating tumorigenesis in HCC cells.
Advanced glycosylation end product-specific receptor
(
AGER
) was identified as a stimulator during this process. Mechanistically,
AGER
activated a hexosamine biosynthetic pathway, leading to enhanced O-GlcNAcylation of target proteins. Notably,
AGER
was capable of increasing activity and stability of proto-oncoprotein
c-Jun
via O-GlcNAcylation of this protein at Ser73. Interestingly,
c-Jun
can conversely enhance
AGER
transcription. Thereby, a positive autoregulatory feedback loop that stimulates diabetic HCC was established. Finally, we found that AG490, an inhibitor of Janus kinase, has the ability to impair
AGER
expression and its functions in HCC cells. In conclusion,
AGER
and its functions to stimulate O-GlcNAcylation are important during liver tumorigenesis, when high blood glucose levels are inadequately controlled.
...
PMID:High Glucose Stimulates Tumorigenesis in Hepatocellular Carcinoma Cells Through AGER-Dependent O-GlcNAcylation of c-Jun. 2682 59